Prevention Strategy of Chemotherapy-Induced Nausea and Vomiting (CINV) with Olanzapine: Alternative Option
International Journal of Advanced Multidisciplinary · 2022
DOI: 10.38035/ijam.v1i3.70 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Advanced Multidisciplinary, 2022. Verfasst von Marizki Pondawinata.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced nausea and vomiting (CINV) is a major problem for patients who use chemotherapy and can lower the quality of life for many cancer patients. If the patient is continuing chemotherapy treatment, then the patient can be certain to experience CINV. Current CINV prevention strategies primarily use 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), dexamethasone, and/or neurokinin-1 receptor antagonists (NK-1 RAs). However, these preventive therapies have not been fully implemented, especially the use of NK-1 RAs because of the high cost. In addition, a standard therapy for CINV prevention is still not effective in controlling CINV symptoms. One alternative CINV preventive therapy option is to use olanzapine. It is an antipsychotic drug that can be used as a preventive therapy for CINV off-label. The purpose of this study is to explain the utilization of olanzapine as alternative choice of antiemetic therapy in preventing CINV.
Zitieren
APA
Pondawinata, M. (2022). Prevention Strategy of Chemotherapy-Induced Nausea and Vomiting (CINV) with Olanzapine: Alternative Option. International Journal of Advanced Multidisciplinary. https://doi.org/10.38035/ijam.v1i3.70
Vancouver
Pondawinata M. Prevention Strategy of Chemotherapy-Induced Nausea and Vomiting (CINV) with Olanzapine: Alternative Option. International Journal of Advanced Multidisciplinary. 2022. doi:10.38035/ijam.v1i3.70
BibTeX
@article{Pondawinata2022,
author = {Pondawinata, Marizki},
title = {Prevention Strategy of Chemotherapy-Induced Nausea and Vomiting (CINV) with Olanzapine: Alternative Option},
journal = {International Journal of Advanced Multidisciplinary},
year = {2022},
doi = {10.38035/ijam.v1i3.70}
}
EUVIMED